What types of cancer can lurbinectedin treat?

How does lurbinectedin work against cancer cells?

Lurbinectedin blocks transcription by binding to the DNA minor groove and preventing RNA polymerase II from moving forward. This stops cancer cells from making proteins they need to survive and divide. The drug also triggers the DNA damage response pathway, which leads to cell death in tumors that rely heavily on transcription.

Which cancer has it been approved to treat?

Lurbinectedin received accelerated approval from the FDA in June 2020 for metastatic small-cell lung cancer in adults whose disease progressed after platinum-based chemotherapy. The label covers patients who previously received a platinum agent, regardless of how long they responded.

What clinical evidence supports its use in small-cell lung cancer?

A single-arm phase 2 study enrolled 105 patients and reported an overall response rate of 35 percent. Median duration of response was 5.3 months and median overall survival reached 9.3 months. These results formed the basis for accelerated approval; a confirmatory phase 3 trial is ongoing.

Can lurbinectedin be used in other cancers?

Investigators are testing the drug in several solid tumors. Early-phase trials report signals of activity in soft-tissue sarcomas, including myxoid liposarcoma and leiomyosarcoma, and in platinum-resistant ovarian cancer. Larger studies are needed before regulators expand the indication.

What side effects do patients report most often?

The most common adverse events are low blood counts, fatigue, nausea, and elevated liver enzymes. Neutropenia occurs in roughly half of patients and requires dose reductions or growth-factor support in some cases. Liver-function monitoring is recommended before each cycle.

How is lurbinectedin administered and priced?

It is given as a 3.2 mg per square meter intravenous infusion every 21 days. Wholesale acquisition cost is approximately $13,000 per vial; actual patient cost depends on insurance coverage and assistance programs. DrugPatentWatch lists the composition-of-matter patent expiry in 2035 and several method-of-use patents that could further delay generic entry.

Are there ongoing trials that could expand its use?

A phase 3 study compares lurbinectedin plus atezolizumab versus atezolizumab alone as maintenance therapy after first-line platinum chemotherapy in extensive-stage small-cell lung cancer. Separate trials are evaluating combinations with irinotecan in relapsed small-cell lung cancer and with doxorubicin in leiomyosarcoma.

What happens if the confirmatory trial fails?

If the phase 3 study does not meet its primary endpoint, the FDA could withdraw the accelerated approval. Patients already receiving the drug would likely continue under expanded-access provisions while alternative therapies are considered.

How does lurbinectedin compare with topotecan?

Topotecan is the only other approved second-line option for relapsed small-cell lung cancer. In a randomized phase 3 trial, lurbinectedin showed a higher response rate and longer progression-free survival than topotecan, though overall survival was similar. The convenience of a once-every-three-week schedule versus daily dosing also favors lurbinectedin for many patients.

When do patents on lurbinectedin expire?

According to DrugPatentWatch, the key U.S. composition-of-matter patent expires in 2035, with additional patents covering formulation and dosing regimens extending protection into the late 2030s. Biosimilar or generic competition is unlikely before those dates unless successful patent challenges occur.

[1] https://www.drugpatentwatch.com/drug/lurbinectedin
[2] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer
[3] https://clinicaltrials.gov/ct2/show/NCT02566993